Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention

Neuro-Oncology

Volumn 14, Issue SUPPL.4, 2012, Pages

  Grisold, Wolfgang ^a   Cavaletti, Guido ^b   Windebank, Anthony J ^c  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c MAYO CLINIC   (United States)

Author keywords

cancer treatment; chemotherapy induced neuropathy; long term effects; neurotoxicity

Indexed keywords

ALANINE GLYOXYLATE AMINOTRANSFERASE; ALPHA INTERFERON; ANASTROZOLE; ANTINEOPLASTIC AGENT; BETA3 INTEGRIN; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CISPLATIN; CYTARABINE; DOCETAXEL; ERIBULIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; GLUTATHIONE TRANSFERASE; IFOSFAMIDE; LENALIDOMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; SURAMIN; TAXANE DERIVATIVE; THALIDOMIDE; VINCA ALKALOID; VINCRISTINE; VINFLUNINE;

AGE DISTRIBUTION; ARTICLE; CANCER SURVIVOR; CLINICAL FEATURE; COMORBIDITY; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DOSE RESPONSE; HEPATITIS C; HUMAN; LEUKEMIA; LONG TERM CARE; LYMPHOMA; MITOSIS SPINDLE; MYALGIA; MYOPATHY; NERVE BIOPSY; NERVE CONDUCTION; NEUROPATHIC PAIN; NEUROTOXICITY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PROGNOSIS; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BIOPSY; SPINAL GANGLION;

ANTINEOPLASTIC AGENTS; HUMANS; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84868008289     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos203     Document Type: Article

References (90)

1. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxic-ity. Nat Rev Neurol. 2010;6:657-666.
2. Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer. 2010;116:2322-2331.
3. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984;34(7):934-938. (Pubitemid 14076460)
4. Cavaletti G, Bogliun G, Marzorati L, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol. 2004;15:1439-1442. (Pubitemid 39295034)
5. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008;34:368-377.
6. Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009;144:245-252.
7. Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology. 1969;19:367-374.
8. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage. 2007;33:166-179. (Pubitemid 46186866)
9. Pal PK. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol. 1999;39:323-330. (Pubitemid 29425922)
10. Chon HJ, Rha SY, Im CK, et al. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat. 2009;41:196-204.
11. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol. 2006;24:1633-1642. (Pubitemid 46638788)
12. Conlin AK, Seidman AD, Bach A, et al. Phase II trial of weekly nanopar-ticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2010;10:281-287.
13. Cardoso F, de Azambuja E, Lago LD. Current perspectives of epothi-lones in breast cancer. Eur J Cancer. 2008;44:341-352.
14. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotox-icity: a clinical and neurophysiologic study. Neurology. 2004;62:2291-2293. (Pubitemid 38787791)
15. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib-and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst. 2008;13(4):275-282.
16. Gilardini A, Marmiroli P, Cavaletti G. Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity? Curr Med Chem. 2008;15:3025-3035.
17. Younes A, Gopal AK, Smith SE, et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. J Clin Oncol. 2012;30:2183-2189.
18. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol (Berl). 1992;84:364-371.
19. Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol. 1998;9:443-447. (Pubitemid 28273039)
20. Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006;27:992-1002. (Pubitemid 44838955)
21. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest. 1998;101:2842-2850. (Pubitemid 28294593)
22. Zhang H, Mizumachi T, Carcel-Trullols J, et al. Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells. Carcinogenesis. 2007;28:1629-1637. (Pubitemid 47289023)
23. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis. 2002;9:220-233. (Pubitemid 34261216)
24. Scuteri A, Galimberti A, Maggioni D, et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology. 2009;30:312-319.
25. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32:51-60. (Pubitemid 40917889)
26. Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry. 1996;35:6806-6814. (Pubitemid 26172439)
27. Sahenk Z, Brady ST, Mendell Jr. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve. 1987;10:80-84. (Pubitemid 17223315)
28. Shemesh OA, Spira ME. Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol. 2010;119:235-248.
29. Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res. 2007;1168:46-59. (Pubitemid 47320623)
30. Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab. 2006;7:677-685. (Pubitemid 44226590)
31. Casafont I, Berciano MT, Lafarga M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res. 2010;17:167-178.
32. Bruna J, Udina E, Ale A, et al. Neurophysiological, histological and im-munohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol. 2010;223(2):599-608.
33. Montagut C, Rovira A, Albanell J. The proteasome: a novel target for anticancer therapy. Clin Transl Oncol. 2006;8(5):313-317.
34. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011;12:1551-1561.
35. Antonacopoulou AG, Argyriou AA, Scopa CD, et al. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur J Neurol. 2010;17:963-968.
36. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13:27-46. (Pubitemid 351393018)
37. Brydøy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009;101:1682-1695.
38. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology. 1999;53:1660-1664. (Pubitemid 29530336)
39. Cavaletti G, Cornblath D, Merdies I, et al. The Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization (CI-PeriNomS) study: from consensus to the first validity and reliability findings. Annals of Oncology. In Press.
40. Wolf SL, Barton DL, Qin R, et al. The relationsship between numbness, tingling and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer. 2012;20:625-632.
41. Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, et al. Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer. 2012;20:877-881.
42. Lauria G, Hsieh ST, Johansson O, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903-912, e44-e49.
43. Grisold A. Chemotherapie induzierte Polyneuropathie. Diploma work at the medical university Vienna: Diplomarbeit, Medizinische Universität Wien (MUW), 2010;1-86.
44. Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with preexisting neuropathy. Neurology. 2003;60:337-340.
45. Gregg RW, Molepo JM, Monpetit VJA, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992;10:795-803.
46. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Safety. 1995;13:228-244.
47. International Collaborative Ovarian NeoPlasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505-515.
48. Argyriou AA, Chroni E, Polychronopoulos P, et al. Efficacy of oxcarba-zepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006;67:2253-2255. (Pubitemid 46035491)
49. Shepherd FA. Phase I study of paclitaxel (taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1996;7:311-313.
50. Fazeny B, Zifko U, Meryn S, et al. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel-a phase II study. Cancer Chemother Pharmacol. 1996;39:150-156. (Pubitemid 26400674)
51. DeAngelis LM, Gnecco C, Taylor L, et al. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer. 1991;67:2241-2246.
52. Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56:361-367.
53. Hilkens PH, Verweij J, Vecht CJ, et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol. 1997;8:187-190. (Pubitemid 27112888)
54. Postma TJ, Vermorken JB, Liefting AJ, et al. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6:489-494.
55. Freilich RJ, Balmaceda C, Seidman AD, et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996;47:115-118. (Pubitemid 26243870)
56. Guastalla JP, Dié ras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer. 2003;89(Suppl 3):16-22.
57. Camps C, Felip E, Sanchez JM, et al. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol. 2005;16:597-601. (Pubitemid 40613326)
58. Jain S, Cigler T. Eribulin mesylate in the treatment of metastatic breast cancer. Biologics. 2012;6:21-29.
59. Chan ML, Stewart AK. Carfilzomib: a novel second-generation protea-some inhibitor. Future Oncol. 2011;7:607-612.
60. Mazumder A, Jagannath S. Thalidomide and lenalidomide in multiple myeloma. Best Pract Res Clin Haematol. 2006;19:769-780. (Pubitemid 44391352)
61. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118:4519-4529.
62. Chaudhry V, Eisenberger MA, Sinibaldi VJ, et al. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996;119:2039-2052. (Pubitemid 27032634)
63. Stein ME, Drumea K, Yarnitsky D, et al. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am J Clin Oncol. 1998;21:248-249. (Pubitemid 28280134)
64. Foyil KV, Bartlett NL. Brentuximab vedotin for the treatment of CD30+ lymphomas. Im-munotherapy. 2011;3:475-485.
65. Toyooka K, Fujimura H. Iatrogenic neuropathies. Curr Opin Neurol. 2009;22:475-479.
66. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmeno-pausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110:244-254. (Pubitemid 47121883)
67. Nishihori T, Choi J, DiGiovanna MP, et al. Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer. Clin Breast Cancer. 2008;8:362-365.
68. Valdivieso M, Kujawa AM, Jones T, et al. Survivors in the United States: A Review of the Literature and a Call to Action. International Journal of Medical Sciences. 2012;9:163-173.
69. Reyes-Gibby C, Morrow PK, Bennett MI, et al. Neuropathic pain in breast cancer survivors: using the ID pain as a screening tool. Outcome and long term survivors. J Pain Symptom Manage. 2010;39:882-889.
70. Matei D, Miller AM, Monahan P, et al. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol. 2009;27:4142-4149.
71. Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl CancerInst. 2010;102:1114-1130.
72. Mykletun A, Dahl AA, Haaland CF, et al. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol. 2005;23:3061-3068. (Pubitemid 46224128)
73. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010;303:1037-1045.
74. Strumberg D, Brügge S, Korn MW, et al. Evaluation of long-term tox-icity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol. 2002;13:229-236. (Pubitemid 34704974)
75. Bernhardson BM, Tishelman C, Rutqvist LE. Chemosensory changes experienced by patients undergoing cancer chemotherapy: a qualitative interview study. J Pain Symptom Manage. 2007;34:403-412. (Pubitemid 47454700)
76. Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cis-platin administration and the development of ototoxicity. J Clin Oncol. 2006;24:918-924. (Pubitemid 46638845)
77. Hile ES, Fitzgerald GK, Studenski SA. Persistent Mobility Disability After Neurotoxic Chemotherapy. Phys Ther. 2010;90:1649-1657.
78. Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556-561.
79. Burton AW, Fanciullo GJ, Beasley RD, et al. Pain in the cancer survivor: a new frontier. Pain Med. 2007;8:189-198.
80. Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20:1767-1774. (Pubitemid 34273265)
81. Pietrangeli A, Leandri M, Terzoli E, et al. Persistence of high-dose oxaliplatin-induced neuropathy at long term follow-up. Eur Neurol. 2006;56:13-16. (Pubitemid 44359537)
82. Brouwers EE, Huitema AD, Boogerd W, et al. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol. 2009; 48:832-841.
83. Denlinger CS, Barsevick AM. Challenges of colorectal cancer survivorship. J Natl Compr Canc Netw. 2009;7:883-893.
84. Haim N, Barron SA, Robinson E. Muscle cramps associated with vincris-tine therapy. Acta Oncol. 1991;30:707-711.
85. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95:311-319.
86. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895-903.
87. Lersch C, Schmelz R, Eckel F, et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2002;2:54-58. (Pubitemid 34704965)
88. Kassem LA, Yassin NA. Role of erythropoeitin in prevention of chemotherapy-induced peripheral neuropathy. Pak J Biol Sci. 2010;13:577-587.
89. Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2011;Feb 16 (2):CD005228.
90. Grisold W, Vass A, Schmidhammer R, et al. Rehabilitation of neuropathies. Crit Rev Physical Rehabil Med. 2007;19:19-53. (Pubitemid 46847184)